For the fiscal year ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-31392 PLURI INC. (Exact name of registrant as specified in its charter) Nevada 98-0351734 (State or other jurisdiction of incorporat ...

Exhibit 99.1 Investor Contact: Adam Hanan (615) 443-9887 Media Contact: Heidi Pearce (615) 235-4135 CRACKER BARREL REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2025 RESULTS AND PROVIDES OUTLOOK LEBANON, Tenn. – September 17, 2025 – Cracker Barrel Old Country Store, Inc. ("Cracker Barrel" or the "Company") (Nasdaq: CBRL) today reported its financial results for the fourth quarter of fiscal 2025 ended August 1, 2025. Cracker Barrel President and Chief Executive Officer Julie Masino said, "We thank our guests f ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32942 EVOLUTION PETROLEUM CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

[Executive Summary](index=1&type=section&id=executive-summary) This section summarizes Rezolute, Inc.'s focus on hyperinsulinism, recent pipeline progress, CEO's strategic outlook, and key financial results for FY2025 [Introduction and Company Focus](index=1&type=section&id=introduction-company-focus) Rezolute, Inc. is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, reporting financial results for the fourth quarter and full fiscal year ended June 30, 2025 - Rezolute, Inc. (Nasdaq: RZLT) is a late-stage rare disease company[1](index=1&type=chunk) - The company focuses on treating hypoglycemia caused by hyperinsulinism[1](index=1&type=chunk) - Financial results are reported for the fourth quarter and full fiscal year ended June 30, 2025[1](index=1&type=chunk) [CEO's Strategic Outlook](index=1&type=section&id=ceo-strategic-outlook) CEO Nevan Charles Elam highlighted substantial progress across both congenital and tumor hyperinsulinism indications for ersodetug, noting FDA alignment on a streamlined Phase 3 trial for tumor HI and anticipating topline results from the sunRIZE trial in December 2025 - Substantial progress has been made across two indications for ersodetug: **congenital and tumor hyperinsulinism**[2](index=2&type=chunk) - FDA alignment on a streamlined Phase 3 trial in tumor hyperinsulinism is seen as recognition of ersodetug's broad applicability and transformative potential[2](index=2&type=chunk) - Topline results from the sunRIZE trial are expected in **December 2025**[2](index=2&type=chunk) [Recent Pipeline Progress and Anticipated Milestones](index=1&type=section&id=recent-pipeline-progress-anticipated-milestones) This section details the latest advancements in ersodetug's clinical development for congenital and tumor hyperinsulinism, including enrollment completion and expected topline results [Congenital Hyperinsulinism (HI) Program](index=1&type=section&id=congenital-hyperinsulinism-hi-program) Rezolute completed enrollment for the sunRIZE Phase 3 study of ersodetug for congenital HI, exceeding targets with 62 participants, and expects topline results in December 2025 - Completed enrollment in sunRIZE, a Phase 3 study for congenital HI, exceeding enrollment with **62 participants** (approximately **15% from U.S. sites**)[5](index=5&type=chunk) - Topline results from the sunRIZE trial are expected in **December 2025**[5](index=5&type=chunk) - **Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE):** | Characteristic | Value | | :------------- | :---- | | Average Age | 3.4 years (35% <2 years old) | | Hypoglycemia Events | 15 (average) per week | | Daily Percent Time in Hypoglycemia | 19% | | Taking ≥1 SOC treatments | 95% | [Tumor HI Program](index=1&type=section&id=tumor-hi-program) The Company achieved FDA alignment on a significantly streamlined clinical development path for its upLIFT Phase 3 study of ersodetug for tumor HI, reducing the study to as few as 16 participants in a single-arm open-label portion, with topline results expected in the second half of 2026 - Achieved FDA alignment on a significantly streamlined clinical development path for the ongoing Phase 3 study (upLIFT) of ersodetug for tumor HI[5](index=5&type=chunk) - The truncated upLIFT study will include as few as **16 participants** and be limited to the single-arm open-label portion, removing the need for a double-blind randomized placebo-controlled trial[5](index=5&type=chunk) - Enrollment for upLIFT is underway, and topline results are expected in the **second half of 2026**[5](index=5&type=chunk) [Corporate Updates](index=2&type=section&id=corporate-updates) This section highlights recent organizational changes, including key personnel appointments, to strengthen the company's commercialization efforts [Key Personnel Appointment](index=2&type=section&id=key-personnel-appointment) In August 2025, Dr. Sunil Karnawat was appointed as Chief Commercial Officer, bringing over 25 years of experience in global biopharmaceutical commercialization to spearhead the launch strategy for ersodetug - Dr. Sunil Karnawat was appointed as Chief Commercial Officer in **August 2025**[13](index=13&type=chunk) - Dr. Karnawat has over **25 years of experience** in global commercialization of biopharmaceuticals and medical devices[13](index=13&type=chunk) - He will spearhead launch strategy and global market readiness for ersodetug, having previously led commercial functions for launching four ultra-rare disease products at Ultragenyx[13](index=13&type=chunk) [Financial Results](index=2&type=section&id=financial-results) This section presents Rezolute's financial performance for Q4 and the full fiscal year 2025, detailing cash position, operating expenses, net loss, and key balance sheet data [Cash, Cash Equivalents and Investments](index=2&type=section&id=cash-cash-equivalents-investments) Rezolute's cash, cash equivalents, and investments in marketable securities increased to $167.9 million as of June 30, 2025, up from $127.1 million a year prior - **Cash, Cash Equivalents and Investments in Marketable Securities:** | Metric | June 30, 2025 (in millions) | June 30, 2024 (in millions) | YoY Change (in millions) | | :------------------------------------ | :-------------------------- | :-------------------------- | :----------- | | Cash, cash equivalents and investments | $167.9 | $127.1 | +$40.8 | [Operating Expenses](index=2&type=section&id=operating-expenses) Total operating expenses increased year-over-year for both Q4 and the full fiscal year 2025, driven primarily by higher R&D expenditures related to clinical trials, manufacturing, and employee costs, as well as increased G&A expenses from professional fees and headcount - **Total Operating Expenses:** | Period | FY2025 (in thousands) | FY2024 (in thousands) | YoY Change (in thousands) | | :----- | :-------------------- | :-------------------- | :--------- | | Q4 | $25,850 | $23,102 | +$2,748 | | Full Year | $79,894 | $70,423 | +$9,471 | [Research and Development (R&D) Expenses](index=2&type=section&id=research-development-expenses) R&D expenses increased in both Q4 and the full fiscal year 2025, primarily due to higher clinical trial, manufacturing, and employee-related costs - **Research and Development (R&D) Expenses:** | Period | FY2025 (in thousands) | FY2024 (in thousands) | YoY Change (in thousands) | | :----- | :-------------------- | :-------------------- | :--------- | | Q4 | $20,863 | $19,089 | +$1,774 | | Full Year | $61,527 | $55,743 | +$5,784 | - The increase in R&D expenses was primarily due to increased expenditures in clinical trial activities, manufacturing costs for ersodetug, and higher employee-related expenses (including compensation and stock-based compensation)[8](index=8&type=chunk) [General and Administrative (G&A) Expenses](index=2&type=section&id=general-administrative-expenses) G&A expenses rose in both Q4 and the full fiscal year 2025, mainly driven by increased professional fees and employee-related costs due to higher headcount - **General and Administrative (G&A) Expenses:** | Period | FY2025 (in thousands) | FY2024 (in thousands) | YoY Change (in thousands) | | :----- | :-------------------- | :-------------------- | :--------- | | Q4 | $4,987 | $4,013 | +$974 | | Full Year | $18,367 | $14,680 | +$3,687 | - The increase in G&A expenses was primarily attributable to professional fees and employee-related expenses due to increased headcount[9](index=9&type=chunk) [Net Loss and EPS](index=2&type=section&id=net-loss-eps) Rezolute reported an increased net loss for both Q4 and the full fiscal year 2025, with basic and diluted net loss per common share also increasing year-over-year - **Net Loss and Basic/Diluted Net Loss Per Common Share:** | Metric | Period | FY2025 (in thousands) | FY2024 (in thousands) | YoY Change (in thousands) | | :----- | :----- | :-------------------- | :-------------------- | :--------- | | Net Loss | Q4 | $(24,390) | $(22,976) | $(1,414) | | Net Loss | Full Year | $(74,412) | $(68,459) | $(5,953) | | Basic and diluted net loss per common share | Q4 | $(0.26) | $(0.44) | +$0.18 | | Basic and diluted net loss per common share | Full Year | $(0.98) | $(1.33) | +$0.35 | [Condensed Consolidated Financial Statements Data](index=4&type=section&id=condensed-consolidated-financial-statements-data) The condensed consolidated financial statements provide detailed data for the statements of operations and balance sheets, showing increases in total assets, working capital, and total stockholders' equity, alongside the reported losses and increased accumulated deficit - **Condensed Consolidated Statements of Operations Data (Selected):** | Metric | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | Year Ended June 30, 2025 (in thousands) | Year Ended June 30, 2024 (in thousands) | | :-------------------------- | :-------------------------------------- | :-------------------------------------- | :------------------------------------ | :------------------------------------ | | Research and development | $20,863 | $19,089 | $61,527 | $55,743 | | General and administrative | $4,987 | $4,013 | $18,367 | $14,680 | | Total operating expenses | $25,850 | $23,102 | $79,894 | $70,423 | | Loss from operations | $(25,850) | $(23,102) | $(79,894) | $(70,423) | | Non-operating income (expenses), net | $1,460 | $126 | $5,482 | $1,964 | | Net loss | $(24,390) | $(22,976) | $(74,412) | $(68,459) | | Basic and diluted net loss per common share | $(0.26) | $(0.44) | $(0.98) | $(1.33) | | Shares used to compute basic and diluted net loss per common share | 94,340 | 52,235 | 75,999 | 51,466 | - **Condensed Consolidated Balance Sheets Data:** | Metric | June 30, 2025 (in thousands) | June 30, 2024 (in thousands) | | :-------------------------------- | :--------------------------- | :--------------------------- | | Cash and cash equivalents | $94,107 | $70,396 | | Investments in marketable debt securities | $73,751 | $56,741 | | Working capital | $159,233 | $119,047 | | Total assets | $175,490 | $132,737 | | Accumulated deficit | $(403,856) | $(329,444) | | Total stockholders' equity | $162,127 | $121,003 | [Product Information](index=2&type=section&id=product-information) This section provides an overview of ersodetug, a fully human monoclonal antibody designed to treat hypoglycemia caused by hyperinsulinism [About Ersodetug](index=2&type=section&id=about-ersodetug) Ersodetug is a fully human monoclonal antibody designed to treat hypoglycemia caused by hyperinsulinism by allosterically binding to the insulin receptor, thereby decreasing over-activation and offering potential universal effectiveness across all forms of HI - Ersodetug is a fully human monoclonal antibody[11](index=11&type=chunk) - It binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in hyperinsulinism (HI), thereby improving hypoglycemia[11](index=11&type=chunk) - Ersodetug has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI, as it acts downstream from the pancreas[11](index=11&type=chunk) [Company Information](index=2&type=section&id=company-information) This section offers a brief profile of Rezolute, Inc., emphasizing its mission as a late-stage rare disease company developing ersodetug for hyperinsulinism [About Rezolute, Inc.](index=2&type=section&id=about-rezolute-inc) Rezolute, Inc. is a late-stage rare disease company focused on hyperinsulinism-induced hypoglycemia, developing ersodetug, an antibody therapy that has demonstrated meaningful clinical benefit for both congenital and tumor HI - Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI)[12](index=12&type=chunk) - The Company's antibody therapy, ersodetug, is designed to treat all forms of HI[12](index=12&type=chunk) - Ersodetug has shown meaningful benefit in clinical trials and real-world use for the treatment of both congenital and tumor HI[12](index=12&type=chunk) [Legal and Investor Information](index=3&type=section&id=legal-investor-information) This section includes important disclosures regarding forward-looking statements and provides contact details for investor relations inquiries [Forward-Looking Statements](index=3&type=section&id=forward-looking-statements) This section contains standard forward-looking statements regarding prospective performance, strategies, and anticipated milestones, including trial results and ersodetug's effectiveness, and advises caution due to inherent uncertainties and risks detailed in SEC filings - The release contains forward-looking statements regarding prospective performance and strategies, covered by safe harbor provisions[14](index=14&type=chunk) - These statements include the timing of topline results from sunRIZE and upLIFT trials, ersodetug's applicability and effectiveness for hyperinsulinism, and clinical trial timelines[14](index=14&type=chunk) - Readers are cautioned that actual results may differ materially from anticipated results due to inherent uncertainties and factors discussed in SEC filings (e.g., Risk Factors in 10-K and 10-Q)[14](index=14&type=chunk) [Contacts](index=3&type=section&id=contacts) This section provides contact information for investor relations inquiries - Contact information for Rezolute, Inc. is provided for inquiries[15](index=15&type=chunk)

Exhibit 99 FOR IMMEDIATE RELEASE September 17, 2025 General Mills Reports Fiscal 2026 First-quarter Results and Reaffirms Full-year Outlook MINNEAPOLIS (September 17, 2025) – General Mills, Inc. (NYSE: GIS) today reported results for its first quarter ended August 24, 2025. "Our primary goal in fiscal 2026 is to restore organic sales growth by investing in greater value, innovation, and product news for consumers," said General Mills Chairman and Chief Executive Officer Jeff Harmening. "I'm pleased that we' ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-31543 FLUX POWER HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-K ____________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE PERIOD FROM TO Commission File Number 0-11559 _________________________________ ...

[Report Highlights](index=1&type=section&id=Report%20Highlights) This section provides a concise overview of Optical Cable Corporation's key financial achievements for the third quarter and first nine months of fiscal year 2025 [Third Quarter 2025 Key Financial Highlights](index=1&type=section&id=Third%20Quarter%202025%20Key%20Financial%20Highlights) Optical Cable Corporation (OCC) reported substantial year-over-year growth in net sales and gross profit for the third quarter of fiscal year 2025, with net sales increasing 22.8% and gross profit increasing 61.2% - OCC reported substantial year-over-year growth in net sales and gross profit for both the third quarter and the first nine months of fiscal year 2025[2](index=2&type=chunk) Q3 FY2025 Key Financial Highlights (YoY) | Metric | Q3 FY2025 | Q3 FY2024 | Change (%) | | :----- | :-------- | :-------- | :--------- | | Net Sales | $19.9M | $16.2M | +22.8% | | Gross Profit | $6.3M | $3.9M | +61.2% | - The company experienced an increase in net sales in both its enterprise and specialty markets, and continues to see general market improvement, including strengthening in military and severe duty markets[3](index=3&type=chunk) [Detailed Financial Results](index=1&type=section&id=Detailed%20Financial%20Results) This section presents a comprehensive analysis of OCC's financial performance for the third quarter and year-to-date fiscal year 2025, covering sales, profit, and expenses [Third Quarter 2025 Performance](index=1&type=section&id=Third%20Quarter%202025%20Performance) OCC demonstrated strong financial performance in Q3 FY2025, marked by significant year-over-year and sequential growth in net sales and gross profit, leading to a return to net income [Net Sales Analysis](index=1&type=section&id=net-sales-analysis-q3) This subsection details OCC's net sales performance for Q3 FY2025, including year-over-year and sequential growth, and geographic contributions Net Sales Performance (Q3 FY2025) | Metric | Q3 FY2025 | Q3 FY2024 | Change (%) | | :----- | :-------- | :-------- | :--------- | | Net Sales (YoY) | $19.9M | $16.2M | +22.8% | | Net Sales (Sequential) | $19.9M | $17.5M (Q2 FY2025) | +13.5% | Geographic Net Sales Growth (Q3 FY2025 YoY) | Region | Change (%) | | :----- | :--------- | | United States | +22.0% | | Outside US | +26.2% | - Sales order backlog/forward load was **$7.1 million** at the end of Q3 FY2025, compared to $7.2 million as of April 30, 2025, $6.6 million as of January 31, 2025, and $5.7 million as of October 31, 2024[5](index=5&type=chunk) [Gross Profit and Margin](index=2&type=section&id=gross-profit-and-margin-q3) This subsection analyzes OCC's gross profit and margin for Q3 FY2025, highlighting year-over-year and sequential changes and contributing factors Gross Profit Performance (Q3 FY2025) | Metric | Q3 FY2025 | Q3 FY2024 | Change ($) | Change (%) | | :----- | :-------- | :-------- | :--------- | :--------- | | Gross Profit (YoY) | $6.3M | $3.9M | +$2.4M | +61.2% | | Gross Profit (Sequential) | $6.3M | $5.3M (Q2 FY2025) | +$1.0M | +18.5% | Gross Profit Margin (Q3 FY2025) | Metric | Q3 FY2025 | Q3 FY2024 | Q2 FY2025 | | :----- | :-------- | :-------- | :-------- | | Margin | 31.7% | 24.2% | 30.4% | - Gross profit benefited from production efficiencies driven by increased volumes and the positive impact of OCC's operating leverage[6](index=6&type=chunk) [Operating Expenses and Profitability](index=2&type=section&id=operating-expenses-and-profitability-q3) This subsection examines OCC's operating expenses and overall profitability for Q3 FY2025, including SG&A and net income/loss - SG&A expenses increased **9.5% to $5.7 million** in Q3 FY2025 (from $5.2 million in Q3 FY2024), primarily due to increases in employee and contracted sales personnel-related costs and shipping costs associated with net sales growth[8](index=8&type=chunk) Net Income (Loss) and EPS (Q3 FY2025 YoY) | Metric | Q3 FY2025 | Q3 FY2024 | | :----- | :-------- | :-------- | | Net Income (Loss) | $302,000 | ($1.6M) | | Basic & Diluted EPS | $0.04 | ($0.20) | [Fiscal Year-to-Date 2025 Performance](index=2&type=section&id=Fiscal%20Year-to-Date%202025%20Performance) For the first nine months of fiscal year 2025, OCC achieved significant year-over-year growth in net sales and gross profit, leading to a substantial reduction in net loss compared to the prior year [Net Sales Analysis (YTD)](index=2&type=section&id=net-sales-analysis-ytd) This subsection details OCC's net sales performance for the first nine months of FY2025, including year-over-year growth and market impacts Net Sales Performance (9M FY2025 YoY) | Metric | 9M FY2025 | 9M FY2024 | Change (%) | | :----- | :-------- | :-------- | :--------- | | Net Sales | $53.2M | $47.2M | +12.8% | Geographic Net Sales Growth (9M FY2025 YoY) | Region | Change (%) | | :----- | :--------- | | United States | +9.8% | | Outside US | +24.9% | - Net sales were positively impacted by general market improvements, including particular strength in OCC's military and severe duty markets[11](index=11&type=chunk) [Gross Profit and Margin (YTD)](index=2&type=section&id=gross-profit-and-margin-ytd) This subsection analyzes OCC's gross profit and margin for the first nine months of FY2025, highlighting year-over-year changes Gross Profit Performance (9M FY2025 YoY) | Metric | 9M FY2025 | 9M FY2024 | Change (%) | | :----- | :-------- | :-------- | :--------- | | Gross Profit | $16.3M | $11.7M | +39.5% | Gross Profit Margin (9M FY2025 YoY) | Metric | 9M FY2025 | 9M FY2024 | | :----- | :-------- | :-------- | | Margin | 30.6% | 24.7% | [Operating Expenses and Profitability (YTD)](index=3&type=section&id=operating-expenses-and-profitability-ytd) This subsection examines OCC's operating expenses and overall profitability for the first nine months of FY2025, including SG&A and net loss - SG&A expenses increased **8.2% to $16.9 million** in 9M FY2025 (from $15.7 million in 9M FY2024), primarily due to increases in employee and contracted sales personnel-related costs and shipping costs[13](index=13&type=chunk) Net Loss and EPS (9M FY2025 YoY) | Metric | 9M FY2025 | 9M FY2024 | | :----- | :-------- | :-------- | | Net Loss | ($1.5M) | ($4.6M) | | Basic & Diluted EPS | ($0.19) | ($0.59) | [Strategic Initiatives](index=3&type=section&id=Strategic%20Initiatives) This section outlines OCC's recent strategic actions, including a key collaboration agreement and associated investment aimed at expanding market reach [Strategic Collaboration and Investment](index=3&type=section&id=Strategic%20Collaboration%20and%20Investment) OCC announced a strategic collaboration agreement with Lightera, LLC to expand product offerings and solutions in the enterprise and data center sectors, which included Lightera making an investment in OCC - On July 7, 2025, OCC and Lightera, LLC announced a strategic collaboration agreement to expand product offerings and solutions to the enterprise sector, the data center sector, as well as an expanded presence in other sectors[15](index=15&type=chunk) - The collaboration involves combining portions of product portfolios to deliver additional integrated cabling and connectivity solution offerings, including certain Lightera products being offered and sold by OCC[15](index=15&type=chunk) - Lightera made an investment in OCC, purchasing shares of common stock and holding **7.24%** of the Company's outstanding shares[16](index=16&type=chunk) [Management Outlook](index=3&type=section&id=Management%20Outlook) This section provides insights from OCC's CEO regarding the company's recent performance, operational leverage, and future growth prospects [CEO's Commentary](index=3&type=section&id=CEO%27s%20Commentary) Neil Wilkin, President and CEO, highlighted Q3 as a strong quarter with significant net sales growth and gross profit expansion, driven by increased demand and operating leverage. He expressed confidence in the company's long-term growth strategy and anticipated further opportunities from the Lightera collaboration - OCC delivered significant net sales growth and gross profit expansion during both the third quarter and first nine months, capturing additional opportunities as demand increased[17](index=17&type=chunk) - The company saw benefits of significant operating leverage, with a **22.8% year-over-year increase in net sales** driving **61.2% gross profit growth**[17](index=17&type=chunk) - Management anticipates the strategic collaboration with Lightera will provide additional growth opportunities and is confident in OCC's market positioning to capture growth and create shareholder value[17](index=17&type=chunk) [Corporate Information](index=4&type=section&id=Corporate%20Information) This section provides essential background on Optical Cable Corporation, including its business scope, innovative technologies, and a disclaimer on forward-looking statements [Company Profile](index=4&type=section&id=Company%20Profile) Optical Cable Corporation (OCC) is a leading manufacturer of fiber optic and copper data communication cabling and connectivity solutions, serving enterprise, harsh environment, specialty, and wireless carrier markets, recognized for pioneering innovative technologies - OCC is a leading manufacturer of a broad range of fiber optic and copper data communication cabling and connectivity solutions primarily for the enterprise market and various harsh environment and specialty markets, and also the wireless carrier market[19](index=19&type=chunk) - The company is internationally recognized for pioneering innovative fiber optic and copper communications technologies, offering integrated suites of high-quality products[19](index=19&type=chunk)[20](index=20&type=chunk) - OCC's solutions cover a broad range of applications including commercial, enterprise network, datacenter, residential, campus installations, and customized products for military, industrial, mining, petrochemical, broadcast, and wireless carrier markets[21](index=21&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section serves as a disclaimer regarding forward-looking information, highlighting inherent risks and uncertainties that could cause actual results to differ materially from expectations, and states that the company disclaims any obligation to update such information - The news release may contain forward-looking information concerning the company's outlook, beliefs, future plans, strategies, and anticipated events[24](index=24&type=chunk) - Such information is subject to known and unknown variables, uncertainties, contingencies, and risks that may cause actual events or results to differ materially from expectations[24](index=24&type=chunk) - The Company expressly disclaims any obligation to update this information, whether as a result of new information, future events or otherwise, except as required by applicable laws and regulations[24](index=24&type=chunk) [Financial Tables](index=5&type=section&id=Financial%20Tables) This section presents the unaudited condensed consolidated financial statements, including statements of operations and balance sheet data for specified periods [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This table presents the unaudited condensed consolidated statements of operations for the three and nine months ended July 31, 2025, and 2024, detailing revenue, costs, expenses, and net income/loss Condensed Consolidated Statements of Operations (Q3 and 9M FY2025, in thousands) | | Three Months Ended | | | Nine Months Ended | | | :--- | :--- | :--- | :--- | :--- | :--- | | | July 31, 2025 | July 31, 2024 | July 31, 2025 | July 31, 2024 | | Net sales | $19,917 | $16,222 | $53,209 | $47,188 | | Cost of goods sold | 13,598 | 12,302 | 36,929 | 35,516 | | Gross profit | 6,319 | 3,920 | 16,280 | 11,672 | | SG&A expenses | 5,737 | 5,237 | 16,939 | 15,650 | | Royalty expense, net | 7 | 7 | 20 | 20 | | Amortization of intangible assets | 13 | 13 | 40 | 40 | | Income (loss) from operations | 562 | (1,337) | (719) | (4,038) | | Interest expense, net | (260) | (301) | (772) | (881) | | Gain on insurance proceeds, net | — | 90 | — | 309 | | Other, net | 4 | (2) | 19 | 47 | | Other income (expense), net | (256) | (213) | (753) | (525) | | Income (loss) before income taxes | 306 | (1,550) | (1,472) | (4,563) | | Income tax expense | 4 | 7 | 31 | 21 | | Net income (loss) | $302 | $(1,557) | $(1,503) | $(4,584) | | Net income (loss) per share: | | | | | | Basic and diluted | $0.04 | $(0.20) | $(0.19) | $(0.59) | | Weighted average shares outstanding: | | | | | | Basic and diluted | 8,395 | 7,739 | 7,901 | 7,753 | [Condensed Consolidated Balance Sheet Data](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheet%20Data) This table provides unaudited condensed consolidated balance sheet data as of July 31, 2025, and October 31, 2024, detailing assets, liabilities, and shareholders' equity Condensed Consolidated Balance Sheet Data (July 31, 2025 vs. October 31, 2024, in thousands) | | July 31, 2025 | October 31, 2024 | | :--- | :--- | :--- | | Cash | $421 | $244 | | Trade accounts receivable, net | 11,078 | 10,946 | | Inventories | 18,697 | 18,725 | | Other current assets | 492 | 685 | | Total current assets | 30,688 | 30,600 | | Non-current assets | 9,480 | 9,758 | | Total assets | $40,168 | $40,358 | | Current liabilities | $16,959 | $15,144 | | Non-current liabilities | 1,777 | 4,372 | | Total liabilities | 18,736 | 19,516 | | Redeemable common stock | 3,202 | — | | Total shareholders' equity | 18,230 | 20,842 | | Total liabilities, redeemable common stock and shareholders' equity | $40,168 | $40,358 | [Investor Relations](index=3&type=section&id=Investor%20Relations) This section provides details for investors regarding the company's conference call to discuss financial results and access information [Conference Call Details](index=3&type=section&id=Conference%20Call%20Details) This section provides information for the conference call to discuss the third quarter fiscal year 2025 financial results, including access details and replay options - OCC hosted a conference call on September 11, 2025, at 4:15 p.m. Eastern Time[18](index=18&type=chunk) - Participants could join by calling (800) 274-8461 (U.S.) or (203) 518-9814 (internationally), using Conference ID: OCCQ325[18](index=18&type=chunk) - A replay was available through September 18, 2025, by dialing (800) 934-8233 or (402) 220-6991, and the call was also broadcast live over the internet via www.occfiber.com[18](index=18&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission file number 000-56016 KAIVAL BRANDS INNOVATIONS GROUP, INC. (Exact name of registrant as specified in its charter) (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2025 OR (State or o ...

[Financial & Operational Highlights](index=1&type=section&id=Second%20Quarter%202025%20Highlights) Crescent Energy reported a strong second quarter of 2025, achieving record production of 263 MBoe/d and generating significant cash flow, successfully reducing costs, executing accretive transactions, repaying debt, and returning capital to shareholders, leading to an enhanced full-year outlook Q2 2025 Financial and Operational Metrics | Metric | Q2 2025 Value | | :--- | :--- | | Average Production | 263 MBoe/d | | Oil Production | 108 Mbo/d | | Net Income | $162 million | | Adjusted Net Income | $110 million | | Adjusted EBITDAX | $514 million | | Operating Cash Flow | $499 million | | Levered Free Cash Flow | $171 million | | Capital Expenditures | $265 million | - Key operational and strategic achievements in Q2 2025 include: - Improved drilling, completion, and facilities (DC&F) costs by approximately **15%** in South Texas and the Uinta compared to 2024 - Repaid approximately **$200 million** of debt using excess free cash flow - Repurchased approximately **$28 million** of shares at an average price of **$7.88** - Simplified corporate structure by eliminating the Up-C structure[6](index=6&type=chunk) [Strategic Activities](index=2&type=section&id=Strategic%20Activities) During the quarter, Crescent continued its portfolio optimization strategy by closing a $72 million minerals acquisition and divesting approximately $110 million in non-core assets year-to-date, while maintaining its shareholder return program through a quarterly dividend and opportunistic share repurchases [Acquisitions and Divestitures](index=2&type=section&id=Acquisitions%20and%20Divestitures) Crescent closed a $72 million accretive minerals acquisition to scale its existing portfolio, with year-to-date divestitures of non-core assets reaching $110 million, including the sale of non-operated assets in the Permian and Eagle Ford basins, as part of a larger $250 million divestiture pipeline - On July 31, 2025, Crescent closed an accretive acquisition of complementary minerals assets for approximately **$72 million**[7](index=7&type=chunk) - Year-to-date, the company has divested approximately **$110 million** of non-core assets, including: - **$83 million** from non-operated Permian Basin assets (closed April 22, 2025) - **$22 million** from non-operated Eagle Ford Basin assets (closed July 30, 2025)[8](index=8&type=chunk) [Shareholder Return](index=2&type=section&id=Shareholder%20Return) The company declared a Q2 2025 cash dividend of $0.12 per share, and additionally repurchased $28 million of its Class A common stock at a weighted average price of $7.88 per share, leaving approximately $86 million available under its $150 million share repurchase program - The Board of Directors approved a Q2 2025 cash dividend of **$0.12 per share**, payable on September 2, 2025[11](index=11&type=chunk) - During Q2, the company repurchased approximately **$28 million** of shares, with **$86 million** remaining under the authorized **$150 million** Share Repurchase Program[12](index=12&type=chunk) [Enhanced 2025 Outlook](index=2&type=section&id=Enhanced%202025%20Outlook) Crescent has enhanced its full-year 2025 guidance, reducing its capital expenditure forecast by approximately 3% while maintaining production targets, and significantly improving the cash tax outlook to 0% of Adjusted EBITDAX, largely due to the new 'One Big Beautiful Bill Act' 2025 Full-Year Outlook Comparison | Metric | Prior 2025 Outlook | Current 2025 Outlook | Change vs. Midpoint | | :--- | :--- | :--- | :--- | | Total Production (MBoe/d) | 251 - 261 | 251 - 261 | 0% | | Capital Expenditures ($MM) | $925 - $1,025 | $910 - $990 | ($25 MM) / (~3%) | | Cash Taxes (% of Adj. EBITDAX) | 2.0% - 5.0% | 0% | (100%) | - The improved outlook reflects ongoing operational efficiencies, modest activity acceleration, and a more favorable tax outlook due to the 'One Big Beautiful Bill Act' (OBBBA) signed into law on July 4, 2025[9](index=9&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) The company's financial statements reflect significant year-over-year growth in production and revenue, driven by acquisitions and operational performance, with net income for Q2 2025 at $162.5 million, total assets at $9.86 billion, and strong operating cash flow of $836.1 million for the first six months of 2025 [Operational Summary](index=5&type=section&id=Crescent%20Operational%20Summary) In Q2 2025, total average daily production increased to 263 MBoe/d from 165 MBoe/d in Q2 2024, a 59% increase, and while realized prices for oil and NGLs before derivatives were lower year-over-year, operating expenses per Boe decreased from $19.61 to $16.31, demonstrating improved cost efficiency Operational Summary: Q2 2025 vs Q2 2024 | Metric | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | Total Production (MBoe/d) | 263 | 165 | +59.4% | | Oil Production (MBbls/d) | 108 | 73 | +47.9% | | Realized Price ($/Boe, pre-hedges) | $35.96 | $41.27 | -12.9% | | Operating Expense ($/Boe) | $16.31 | $19.61 | -16.8% | [Income Statement](index=6&type=section&id=Crescent%20Condensed%20Consolidated%20Income%20Statement) For Q2 2025, Crescent reported total revenues of $898.0 million, up from $653.3 million in Q2 2024, driven by higher production volumes, with net income attributable to Crescent Energy at $153.2 million ($0.61 per basic share), a significant increase from $37.5 million ($0.34 per basic share) in the prior-year quarter, aided by a large gain on derivatives Condensed Consolidated Income Statement (Thousands) | (in thousands) | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Total Revenues | $897,983 | $653,283 | | Income from Operations | $79,635 | $119,384 | | Net Income | $162,498 | $70,205 | | Net Income Attributable to Crescent | $153,221 | $37,547 | | EPS (Class A, basic) | $0.61 | $0.34 | [Balance Sheet](index=7&type=section&id=Crescent%20Condensed%20Consolidated%20Balance%20Sheet) As of June 30, 2025, Crescent's total assets stood at $9.86 billion, up from $9.16 billion at year-end 2024, with total liabilities increasing to $5.36 billion from $4.79 billion, primarily due to a rise in long-term debt to $3.37 billion, while total equity grew to $4.50 billion, strengthened by the elimination of redeemable noncontrolling interests following the corporate simplification Condensed Consolidated Balance Sheet (Thousands) | (in thousands) | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Total Current Assets | $753,271 | $788,088 | | Property, Plant and Equipment, net | $8,980,400 | $8,145,054 | | **Total Assets** | **$9,856,686** | **$9,160,649** | | Total Current Liabilities | $851,595 | $827,363 | | Long-term Debt | $3,373,595 | $3,049,255 | | **Total Liabilities** | **$5,357,962** | **$4,792,689** | | **Total Equity** | **$4,498,724** | **$3,139,631** | [Cash Flow Statement](index=9&type=section&id=Crescent%20Condensed%20Consolidated%20Cash%20Flow%20Statement) For the six months ended June 30, 2025, net cash from operating activities was $836.1 million, a significant increase from $470.7 million in the same period of 2024, with net cash used in investing activities at $1.27 billion, primarily for property acquisitions and development, and financing activities providing $213.4 million in net cash Condensed Consolidated Cash Flow Statement (Thousands) | (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $836,080 | $470,696 | | Net cash used in investing activities | ($1,269,111) | ($286,562) | | Net cash provided by (used in) financing activities | $213,380 | $594,461 | [Non-GAAP Financial Measures](index=10&type=section&id=Reconciliation%20of%20Non-GAAP%20Measures) The company provides reconciliations for key non-GAAP metrics used by management and investors to evaluate performance, with Q2 2025 Adjusted EBITDAX at $513.9 million, Levered Free Cash Flow at $170.9 million, Adjusted Net Income at $110.3 million, and a Net LTM Leverage ratio of 1.5x as of June 30, 2025 [Adjusted EBITDAX and Levered Free Cash Flow](index=10&type=section&id=Adjusted%20EBITDAX%20and%20Levered%20Free%20Cash%20Flow) Adjusted EBITDAX for Q2 2025 was $513.9 million, up from $319.8 million in Q2 2024, and after accounting for interest, taxes, and capital expenditures, the company generated $170.9 million in Levered Free Cash Flow for the quarter, compared to $146.9 million in the prior-year period Adjusted EBITDAX and Levered Free Cash Flow Reconciliation (Thousands) | (in thousands) | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Net income (loss) | $162,498 | $70,205 | | **Adjusted EBITDAX (non-GAAP)** | **$513,854** | **$319,774** | | **Levered Free Cash Flow (non-GAAP)** | **$170,875** | **$146,933** | [Adjusted Net Income](index=12&type=section&id=Adjusted%20Net%20Income) Adjusted Net Income, which excludes items like unrealized derivative gains/losses and non-cash compensation, was $110.3 million ($0.43 per share) for Q2 2025, representing a significant increase from the $56.2 million ($0.31 per share) reported in Q2 2024 Adjusted Net Income Reconciliation (Thousands) | (in thousands, except EPS) | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Net income (loss) | $162,498 | $70,205 | | **Adjusted Net Income (non-GAAP)** | **$110,255** | **$56,155** | | **Adjusted EPS** | **$0.43** | **$0.31** | [Net LTM Leverage](index=13&type=section&id=Net%20LTM%20Leverage) As of June 30, 2025, Crescent's Net LTM Leverage ratio, calculated as net debt divided by LTM Adjusted EBITDAX under its credit agreement, was 1.5x, based on net debt of $3.37 billion and LTM Adjusted EBITDAX of $2.28 billion Net LTM Leverage Calculation (Millions) | (in millions) | June 30, 2025 | | :--- | :--- | | Net Debt | $3,371 | | LTM Adjusted EBITDAX for Leverage Ratio | $2,284 | | **Net LTM Leverage** | **1.5x** |